Who are Acetaminophen solid formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BENZHYDROCODONE, Duragesic, Codeine, MEPERIDINE, MS Contin, Standard Care morphine hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acetaminophen-solid-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Acetaminophen solid formulation — Competitive Intelligence Brief

Acetaminophen solid formulation (Acetaminophen solid formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: analgesic. Area: Pain Management.

phase 1 analgesic cyclooxygenase (COX) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Acetaminophen solid formulation (Acetaminophen solid formulation) — Beth Israel Deaconess Medical Center. Acetaminophen exerts its analgesic and antipyretic effects primarily through inhibition of cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acetaminophen solid formulation TARGET	Acetaminophen solid formulation	Beth Israel Deaconess Medical Center	phase 1	analgesic	cyclooxygenase (COX)
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
Duragesic	fentanyl	Johnson & Johnson (Janssen Pharmaceutica)	marketed	Synthetic opioid analgesic	D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor	1968-01-01
Codeine	codeine phosphate	Generic (multiple manufacturers)	marketed	Opioid analgesic, Antitussive	Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor	1950-01-01
MEPERIDINE	MEPERIDINE		marketed	opioid analgesic	mu-opioid receptor	1942-01-01
MS Contin	morphine sulfate	Generic (multiple manufacturers)	marketed	Opioid analgesic	Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor	1941-01-01
Standard Care morphine hydrochloride	Standard Care morphine hydrochloride	Centre Hospitalier Universitaire de Nīmes	marketed	Opioid analgesic	Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-01-25 — Duragesic · 10610523 · Formulation · US
2027-01-25 — Duragesic · 8835460 · Formulation · US
2027-01-25 — Duragesic · 9642797 · Formulation · US
2027-01-25 — Duragesic · 9289387 · Formulation · US
2027-01-25 — Duragesic · 10016403 · Formulation · US
2027-01-25 — Duragesic · 9241935 · Formulation · US
2027-01-25 — Duragesic · 9642844 · Formulation · US
2027-01-25 — Duragesic · 8835459 · Formulation · US
2028-08-12 — MS Contin · 10314788 · Formulation · US
2028-08-12 — MS Contin · 7955619 · Formulation · US
2030-04-27 — Duragesic · 8486973 · Method of Use · US
2030-04-27 — Duragesic · 8486972 · Formulation · US
2033-07-01 — MS Contin · 9044402 · Formulation · US
2033-07-01 — MS Contin · 9549899 · Formulation · US
2034-03-12 — MS Contin · 9248229 · Formulation · US
2034-03-12 — MS Contin · 9192608 · Method of Use · US
2034-03-12 — MS Contin · 9072781 · Formulation · US

Sponsor landscape (analgesic class)

Beth Israel Deaconess Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acetaminophen solid formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/acetaminophen-solid-formulation. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab